Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL7320428 | 0.88 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL5187479 | 0.84 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL27709002 | 0.82 | CA1 (0.40) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL542816 | 0.81 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL9460589 | 0.81 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL2290380 | 0.81 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL28243370 | 0.81 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL27964313 | 0.81 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL295 | 0.80 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL39465 | 0.80 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396218-A | Synthesis method of benzazepine compound | 南京师范大学 | 2023-07-07 | — | — | CN | claimed |
| CN-111448205-B | Vaccine against klebsiella pneumoniae | 爱杜西亚药品有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-116396218-A | Synthesis method of benzazepine compound | 南京师范大学 | 2023-07-07 | — | — | CN | disclosed |
| US-6908989-B2 | Process for the production of perbenzylated 1-O-glycosides | SCHERING AG (DE) | 2005-06-21 | — | — | US | disclosed |
| US-6831164-B2 | Generation of peracylated 1-O-glycosides; obtain chemical intermediate, react with alkylating agent, heat and recover product | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-14 | — | — | US | disclosed |
| US-20030069402-A1 | Process for the production of peracylated 1-0-glycosides | SCHERING AG (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6545135-B2 | Alkylation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| EP-1257558-A1 | METHODS FOR SYNTHESIS OF ALPHA-D-GAL (1- 3) GAL-CONTAINING OLIGOSACCHARIDES | Alchemia Pty Ltd (AU) | 2002-11-20 | — | — | EP | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
| EP-0923528-A1 | OLIGOSACCHARIDE SYNTHESIS | Alchemia Pty. Ltd. (AU) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008799-A1 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY. LTD. (AU) | 1998-03-05 | — | — | WO | disclosed |
| WO-1997007810-A1 | COMPOUNDS FOR STIMULATING NERVE GROWTH | THE JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1997-03-06 | — | — | WO | disclosed |
| EP-0579196-B1 | Glycolipid derivatives | NISSHIN OIL MILLS LTD (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0706528-A1 | FUCOSYLATED GLYCOSIDES AS INHIBITORS OF BACTERIAL ADHERENCE | Astra Aktiebolag (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995000527-A1 | FUCOSYLATED GLYCOSIDES AS INHIBITORS OF BACTERIAL ADHERENCE | ASTRA AKTIEBOLAG (SE) | 1995-01-05 | — | — | WO | disclosed |
| US-5369096-A | Antiinflammatory | THE NISSHIN OIL MILLS, LTD. (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0579196-A1 | Glycolipid derivatives | The Nisshin Oil Mills, Ltd. (JP) | 1994-01-19 | — | — | EP | disclosed |
| WO-1992018546-A1 | SULFATED POLYSACCHARIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | GLYCOMED, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| US-5138044-A | Synthesis of sialosides | GLYCOMED, INC. (US) | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | MAN1B1, STT3B, OSTC | ALDH1A1 601/4885L3MBTL1 2534/4885CA1 1706/4885 |
| US-20030069402-A1 | Process for the production of peracylated 1-0-glycosides | B3GNT2, UGT8, UGGT1 | ALDH1A1 723/4885L3MBTL1 775/4885CA1 4025/4885 |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | ALDH1A1 554/4885L3MBTL1 2460/4885CA1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.